Literature DB >> 31106414

From clinic to mechanism: Proteomics-based assessment of angiogenesis in adrenal pheochromocytoma.

Fukang Sun1, Ran Zhuo1, Wenming Ma1, Da Yang1, Tingwei Su2,3, Lei Ye2,3, Danfeng Xu1, Weiqing Wang2,3.   

Abstract

Adrenal pheochromocytoma (PCC) is a very rare tumor that stems from chromaffin cells, which can develop into malignant tumor. During the operation, abundant blood vessels were often observed in PCC than other adrenal tumors, which increases the difficulty and risk of the surgery. Therefore, it is important to investigate the mechanism of PCC angiogenesis. Twelve surgical specimens of PCC from Ruijin Hospital, Shanghai Jiaotong University were grouped into high and low microvessel density (MVD) group. They were also divided into rich blood supply and nonenriched blood supply group, according to computed tomography (CT) manifestation. Comparative proteomic analysis based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) and bioinformatics analysis revealed that 206 proteins differentially regulated in the high MVD group compared with low MVD group (p < 0.05). Besides, 61 proteins were discovered to be significantly changed when the 12 samples were grouped according to CT manifestation. By intersecting the differentially changed protein from MVD and CT grouping, 25 proteins were filtered out, with pathological function. COX4I2 was verified to be increased gradually with angiogenesis with increasing severity, and PLAT was shown to be decreased with angiogenesis in PCC, by quantitative reverse-transcription polymerase chain reaction and immunohistochemistry. The quantitative proteomics result indicated that the tumor angiogenesis in PCC is associated with hypoxia. COX4I2 and PLAT were highly correlated with blood supply in PCC which contribute to angiogenesis in PCC, which could be used as biomarkers to better indicate tumor angiogenesis, or targets to regress tumor angiogenesis as treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiogenesis; computed tomography; microvessel density; pheochromocytoma; quantitative proteomics

Mesh:

Substances:

Year:  2019        PMID: 31106414     DOI: 10.1002/jcp.28769

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  Nano-liquid chromatography-mass spectrometry and recent applications in omics investigations.

Authors:  Katherine L Sanders; James L Edwards
Journal:  Anal Methods       Date:  2020-09-09       Impact factor: 2.896

Review 2.  Adrenal pheochromocytoma: is it all or the tip of the iceberg?

Authors:  Ke Wang; Guanglei Tang; Yang Peng; Chang Li; Wenhao Fu; Ruixi Li; Jian Guan
Journal:  Jpn J Radiol       Date:  2021-09-21       Impact factor: 2.374

3.  Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.

Authors:  Anan Yin; Zhende Shang; Amandine Etcheverry; Yalong He; Marc Aubry; Nan Lu; Yuhe Liu; Jean Mosser; Wei Lin; Xiang Zhang; Yu Dong
Journal:  Oncoimmunology       Date:  2021-03-29       Impact factor: 8.110

4.  A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.

Authors:  Xin Zhong; Feichao Xuan; Yun Qian; Junhai Pan; Suihan Wang; Wenchao Chen; Tianyu Lin; Hepan Zhu; Xianfa Wang; Guanyu Wang
Journal:  BMC Cancer       Date:  2021-04-23       Impact factor: 4.430

5.  COX4I2 is a novel biomarker of blood supply in adrenal tumors.

Authors:  Yongxin Mao; Wenming Ma; Ran Zhuo; Lei Ye; Danfeng Xu; Weiqing Wang; Guang Ning; Fukang Sun
Journal:  Transl Androl Urol       Date:  2021-07

6.  Robotic adrenalectomy versus laparoscopic adrenalectomy for pheochromocytoma: a systematic review and meta-analysis.

Authors:  Lei Du; Zhan Yang; Jinchun Qi; Yaxuan Wang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-07-13       Impact factor: 1.195

7.  Fibroblasts mediate the angiogenesis of pheochromocytoma by increasing COX4I2 expression.

Authors:  Yongxin Mao; Ran Zhuo; Wenming Ma; Jun Dai; Parehe Alimu; Chen Fang; Danfeng Xu; Lei Ye; Weiqing Wang; Fukang Sun
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.